Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

NYSEHealthcareMedical - Devices
Latest quote
$83.52
−$0.72 · -0.85%
Regular session
$83.45
−$0.79 · -0.94%
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
34
Expensive
Sentiment
65
Bullish
Risk
21
Moderate Risk
Momentum
55
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Day range
Current $83.45
52-week range
Current $83.45
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.07B USD | 5.44B USD | 5.01B USD | 5.38B USD | 5.23B USD |
| Cost of goods sold | 1.33B USD | 1.12B USD | 1.04B USD | 1.17B USD | 1.23B USD |
| Gross profit | 4.74B USD | 4.32B USD | 3.97B USD | 4.22B USD | 4.01B USD |
| Research and development | 1.08B USD | 1.05B USD | 962.9M USD | 945.2M USD | 903.1M USD |
| Selling, general, and administrative | 2.09B USD | 1.79B USD | 1.58B USD | 1.57B USD | 1.49B USD |
| Operating expenses | 3.1B USD | 2.94B USD | 2.55B USD | 2.51B USD | 2.4B USD |
| Interest income | 148.4M USD | 120.3M USD | 67.2M USD | 35.5M USD | 17.4M USD |
| Interest expense | — | 19.8M USD | 17.6M USD | 26.2M USD | 24.8M USD |
| Depreciation and amortization | 156.6M USD | 155.2M USD | 144.9M USD | 139.6M USD | 134.8M USD |
| Operating income | 1.64B USD | 1.38B USD | 1.43B USD | 1.7B USD | 1.61B USD |
| Net income | 1.07B USD | 4.17B USD | 1.4B USD | 1.52B USD | 1.5B USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$101.7
21.87% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 1, 2020 | 3:1 | — | — |
Stock split | Dec 14, 2015 | 2:1 | — | — |
Stock split | May 28, 2010 | 2:1 | — | — |
Effective Jun 1, 2020
3:1
Effective Dec 14, 2015
2:1
Effective May 28, 2010
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T95.42B0.07%129.69T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI1.66B0.07%2.3T USD0.03%$381.27+0.45%
Vanguard S&P 500 ETFVOO1.39B0.08%1.8T USD0.03%$714.34+0.43%
Vanguard Morningstar Mid-Cap ETFVO1.13B0.50%226.4B USD0.03%$80.935+0.67%
iShares Core S&P 500 ETFIVV645.72M0.07%897.2B USD0.03%$780.55+0.42%
State Street SPDR S&P 500 ETFSPY603.19M0.07%821.54B USD0.09%$777.1+0.41%
Vanguard Morningstar Value ETFVTV499.21M0.19%262.4B USD0.03%$220.11+0.22%
Vanguard Morningstar Mid-Cap Growth ETFVOT401.43M1.17%34.1B USD0.05%$301.14+1.10%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
Vanguard Morningstar Mid-Cap Growth ETFVOTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.